Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

Lancet Neurology
Daniel OntanedaJeremy Chataway

Abstract

Progressive multiple sclerosis is characterised clinically by the gradual accrual of disability independent of relapses and can occur with disease onset (primary progressive) or can be preceded by a relapsing disease course (secondary progressive). An effective disease-modifying treatment for progressive multiple sclerosis has not yet been identified, and so far the results of clinical trials have generally been disappointing. Ongoing advances in the knowledge of pathogenesis, in the identification of novel targets for neuroprotection, and in improved outcome measures could lead to effective treatments for progressive multiple sclerosis. In this Series paper, we summarise the lessons learned from completed clinical trials and perspectives from trials in progress in progressive multiple sclerosis. We review promising clinical, imaging, and biological markers, along with novel designs, for clinical trials. The use of more refined outcomes and truly neuroprotective drugs, coupled with more efficient trial design, has the capacity to deliver a new era of therapeutic discovery in this challenging area.

References

Apr 1, 1977·Perceptual and Motor Skills·D M Gronwall
Jan 1, 1991·European Neurology·M H Verdier-TailleferA Alpérovitch
Feb 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·N M MilliganD A Compston
Feb 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·C M WilesP H Richardson
Mar 1, 1994·Journal of Magnetic Resonance Imaging : JMRI·J R MitchellA Fenster
Feb 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·E BeutlerJ Zyroff
Feb 7, 1998·Journal of the Neurological Sciences·S D CookT Volmer
Jan 29, 1998·The New England Journal of Medicine·B D TrappL Bö
Mar 8, 1998·PharmacoEconomics·J A JohnsonG Szava-Kovats
Jun 4, 1999·Brain : a Journal of Neurology·G R CutterE Willoughby
Apr 25, 2000·Brain : a Journal of Neurology·J HobartA Thompson
Feb 24, 2001·Multiple Sclerosis : Clinical and Laboratory Research·R A RudickJ Simon
Feb 24, 2001·Multiple Sclerosis : Clinical and Laboratory Research·E FisherN A Simonian
May 4, 2001·Brain : a Journal of Neurology·J HobartA Thompson
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Nov 29, 2001·Multiple Sclerosis : Clinical and Laboratory Research·S SkurkovichE Gusev
Dec 12, 2001·Neurology·L KapposUNKNOWN European Study Group in Interferon beta-1b in Secondary-Progressive MS
Apr 9, 2002·Multiple Sclerosis : Clinical and Laboratory Research·F D Lublin
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Sep 24, 2002·Brain : a Journal of Neurology·Tanja KuhlmannWolfgang Brück

❮ Previous
Next ❯

Citations

Dec 25, 2015·Expert Opinion on Drug Metabolism & Toxicology·Laure Peyro Saint PaulGilles L Defer
Nov 5, 2015·Expert Review of Clinical Pharmacology·Simona E Constantinescu, Cris S Constantinescu
Nov 26, 2015·NeuroImage. Clinical·Shannon KolindPeter A Brex
Jan 6, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Afsaneh ShiraniOlaf Stüve
Feb 3, 2016·Journal of Alzheimer's Disease : JAD·Jun WangJin-Tai Yu
Nov 21, 2015·Nature Reviews. Neurology·Georgia MandolesiDiego Centonze
Jul 5, 2015·Journal of Autoimmunity·Jill A Hollenbach, Jorge R Oksenberg
Mar 19, 2016·Trends in Neurosciences·Catherine LarochelleFrauke Zipp
Mar 30, 2016·Nature Reviews. Neurology·Andrew L Smith, Jeffrey A Cohen
Mar 17, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Heinz WiendlStefan Schwab
Mar 17, 2015·Lancet Neurology·Alan J Thompson
Mar 17, 2015·Lancet Neurology·Timothy CoetzeeTrevis L Gleason
May 12, 2016·CNS Drugs·Domenico PlantoneJeremy Chataway
Jun 7, 2016·Dental Clinics of North America·Miriam R Robbins
Jul 13, 2016·Brain : a Journal of Neurology·Johannes LorscheiderUNKNOWN MSBase Study Group
Aug 25, 2016·Trends in Pharmacological Sciences·P ZaratinM Panzara
Oct 22, 2016·Expert Review of Neurotherapeutics·Catalina CoclituRadu Tanasescu
Nov 1, 2016·Brain : a Journal of Neurology·Jorge CorrealeMarcela P Fiol
Nov 5, 2016·Expert Review of Neurotherapeutics·Alberto GajofattoMaria Donata Benedetti
Nov 7, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Jeremy Chataway
Sep 24, 2016·AJNR. American Journal of Neuroradiology·D OntanedaR J Fox
Oct 7, 2015·Multiple Sclerosis : Clinical and Laboratory Research·Timothy Coetzee
Jan 21, 2016·Therapeutic Advances in Neurological Disorders·Finn SellebjergDaniel Mikol
Jan 21, 2017·CNS Drugs·Benjamin V IneichenMartin E Schwab
Jun 25, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Hideaki NishiharaTakashi Kanda
Aug 3, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Karen SchreiberPer Soelberg Sorensen
Apr 25, 2017·PloS One·Matilde IngleseMaria Pia Sormani
May 10, 2017·Expert Opinion on Pharmacotherapy·Arianna SartoriPaolo Manganotti
Jul 21, 2017·Cell Death & Disease·Haoliang HuangYang Hu
Apr 4, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Benjamin V IneichenThomas M Kessler
Apr 12, 2018·Expert Opinion on Emerging Drugs·Ram Narendra NarayanOlaf Stüve
May 19, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Jeppe Romme ChristensenFinn Sellebjerg
May 22, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Charidimos TsagkasKatrin Parmar
Dec 3, 2017·Clinical Medicine : Journal of the Royal College of Physicians of London·Anisha Doshi, Jeremy Chataway
Oct 19, 2017·Multiple Sclerosis : Clinical and Laboratory Research·P ZaratinD Leppert
Oct 19, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Robert J Fox, Jeremy Chataway
Oct 19, 2017·Multiple Sclerosis : Clinical and Laboratory Research·Matteo PardiniMaria Pia Sormani
Dec 21, 2016·Wellcome Open Research·Alex LewinCharles R M Bangham
Dec 23, 2017·Health and Quality of Life Outcomes·Kirsten M FiestRuth Ann Marrie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

© 2021 Meta ULC. All rights reserved